Protective effect of edaravone against PrP106-126 - Induced PC12 cell death

Journal of Biochemical and Molecular Toxicology

Volumn 24, Issue 4, 2010, Pages 235-241

  Pan, Yong Hui ^a   Wang, Yong Chen ^a   Zhang, Li Ming ^a   Duan, Shu Rong ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Edaravone; Oxidative stress; PC12 cells; PrP106 126

Indexed keywords

CASPASE 3; GLUTATHIONE; MALONALDEHYDE; NORPHENAZONE; PRION PROTEIN; PRION PROTEIN[106-126]; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DEATH; CELL PROTECTION; CELL STRAIN; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; LIPID PEROXIDATION; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; RAT;

ANIMALS; ANTIPYRINE; CASPASE 3; CELL DEATH; FREE RADICAL SCAVENGERS; GLUTATHIONE; LIPID PEROXIDATION; MALONDIALDEHYDE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIAL MEMBRANES; PC12 CELLS; PRPC PROTEINS; RATS; SUPEROXIDE DISMUTASE;

EID: 77956400111     PISSN: 10956670     EISSN: 10990461     Source Type: Journal    
DOI: 10.1002/jbt.20330     Document Type: Article

References (35)

1. Schroder HC, Muller WE. Neuroprotective effect of flupirtine in prion disease. Drugs Today 2002;38:49-58.
2. Andreyev AY, Kushnareva YE, Starkov AA. Mitochondrial metabolism of reactive oxygen species. Biochemistry 2005;70:200-214.
3. Watanabe K, Ma M, Wen J. Effects of edaravone in heart of aged rats after cerebral ischemia-reperfusion injury. Biol Pharm Bull 2007;30:460-464.
4. Dohi K, Satoh K, Nakamachi T, Yofu S, Hiratsuka K, Nakamura S, Ohtaki H, Yoshikawa T, Shioda S, Aruga T. Does edaravone (MCI-186) act as an antioxidant and a neuroprotector in experimental traumatic brain injury? Antiox Redox Signal 2007;9:281-287.
5. Anantharam V, Kanthasamy A, Choi CJ, Martin DP, Latchoumycandane C, Richt JA, Kanthasamy AG. Opposing roles of prion protein in oxidative stress- and ER stress-induced apoptotic signaling. Free Rad Biol Med 2008;45:1530-1541.
6. Choi CJ, Kanthasamy A, Anantharam V, Kanthasamy AG. Interaction of metals with prion protein: possible role of divalent cations in the pathogenesis of prion diseases. Neurotoxicol 2006;27:777-787.
7. Brazier MW, Doctrow SR, Masters CL, Collins SJA. manganese-superoxide dismutase/catalase mimetic extends survival in a mouse model of human prion disease. Free Rad Biol Med 2008;45:184-192.
8. Ferreiro E, Resende R, Costa R, Oliveira CR, Pereira CM. An endoplasmic-reticulum-specific apoptotic pathway is involved in prion and amyloid-beta peptides neurotoxicity. Neurobiol Dis 2006;23:669-678.
9. Turnbull S, Tabner BJ, Brown DR, Allsop D. Quinacrine acts as an antioxidant and reduces the toxicity of the prion peptide PrP106-126. Neuroreport 2003;14:1743-1745.
10. Rubenstein R, Carp RI, Callahan SM. In vitro replication of scrapie agent in a neuronal model: infection of PC12 cells. J Gen Virol 1984;65:2191-2198.
11. Rubenstein R, Deng H, Scalica C, Papini MC. Alterations in neurotransmitter-related enzyme activity in scrapie-infected PC12 cells. J Gen Virol 1991;72:1279-1285.
12. Ciesielski-Treska J, Grant NJ, Ulrich G, Corrotte M, Bailly Y, Haeberle AM, Chasserot-Golaz S, Bader MF. Fibrillar prion peptide (106-126) and scrapie prion protein hamper phagocytosis in microglia. Glia 2004;46:101-115.
13. Sponne I, Fifre A, Koziel V, Kriem B, Oster T, Pillot T. Human in rescues cortical neurons from prion-peptide-induced apoptosis. Mol Cell Neurosci 2004;25:95-102.
14. + -induced cytotoxicity in rat primary cultured astrocytes via inhibition of mitochondrial apoptotic pathway. J Neurochem 2008;106:2345-2352.
15. Kaur C, Ling EA. Antioxidants and neuroprotection in the adult and developing central nervous system. Curr Med Chem 2008;15:3068-3080.
16. Liu XY, Yao LL, Chen YJ, Tao BB, Yu YC, Bian WH, Yu J, Wang YG. Survivin is involved in the anti-apoptotic effect of edaravone in PC12 cells. Mol Cell Biochem 2009; Feb 18. (Epub ahead of print)
17. Song Y, Zli M, Li JC, Wei EQ. Edaravone protects PC12 cells from ischemic-like injury via attenuating the damage to mitochondria. J Zhejiang Univ Sci B 2006;7:749-756.
18. Okatani Y, Wakatsuki A, Enzan H, Miyahara Y. Edaravone protects against ischemia/reperfusion-induced oxidative damage to mitochondria in rat liver. Eur J Pharmacol 2003;465:163-170.
19. Akao T, Takeyoshi I, Totsuka O, Arakawa K, Muraoka M, Kobayashi K, Konno K, Matsumoto K, Morishita Y. Effect of the free radical scavenger MCI-186 on pulmonary ischemia-reperfusion injury in dogs. J Heart Lung Transplant 2006;25:965-971.
20. Amemiya S, Kamiya T, Nito C, Inaba T, Kato K, Ueda M, Shimazaki K, Katayama Y. Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats. Eur J Pharmacol 2005;516:125-130.
21. Suzuki K, Kazui T, Terada H, Umemura K, Ikeda Y, Bashar AH, Yamashita K, Washiyama N, Suzuki T, Ohkura K, Yasuike J. Experimental study on the protective effects of edaravone against ischemic spinal cord injury. J Thorac Cardiovasc Surg 2005;130:1586-1592.
22. Bolton DC, McKinley MP, Prusiner SB. Identification of a protein that purifies with the scrapie prion. Science 1982;218:1309-1311.
23. Diringer H, Ehlers B. Chemoprophylaxis of scrapie in mice. J Gen Virol 1991;72:457-460.
24. Villa A, Mark AE, Saracino GA, Cosentino U, Pitea D, Moro G, Salmona M, Cosentino U, Pitea D, Moro G, Salmona M. Conformational polymorphism of the PrP106-126 peptide in different environments: a molecular dynamics study. J Phys Chem B 2006;110:1423-1428.
25. Brown DR, Schmidt B, Kretzschmar HA. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature 1996;380:345-347.
26. Brown DR, Schulz-Schaeffer WJ, Schmidt B, Kretzschmar HA. Prion protein-deficient cells show altered response to oxidative stress due to decreased SOD-1 activity. Exper Neurol 1997;146:104-112.
27. Heppner FL, Aguzzi A. Recent developments in prion immunotherapy. Curr Opin Immunol 2004;16:594-598.
28. Brown DR. Neurodegeneration and oxidative stress: prion disease results from loss of antioxidant defence. Folia Neuropathol 2005;43:229-243.
29. Brown DR, Schmidt B, Kretzschmar HA. Effects of oxidative stress on prion protein expression in PC12 cells. J Dev Neurosci 1997;15:961-972.
30. Brimble MA, Levi MS. A review of agents patented for their neuroprotective properties. Recent Pat. CNS Drug Discov 2006;1:139-146.
31. The Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003;15:222-229.
32. Yoshinoya H, Kimura A. Clinical trial for amyotrophic lateral sclerosis with free radical scavenger, edaravone. In: Noseworthy JH, editor. Neurological therapeutics. London: Martin Dunitz; 2003. Vol 2, pp 557-564.
33. Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study). Amyotroph Lateral Scler 2006;7:241-245.
34. Yamawaki M, Sasaki N, Shimoyama M, Miake J, Ogino K, Igawa O, Tajima F, Shigemasa C. Hisatome, I. Protective effect of edaravone against hypoxia-reoxygenation injury in rabbit cardiomyocytes. Br J Pharmacol 2004;142:618-626.
35. Kono H, Woods CG, Maki A, Connor HD, Mason RP, Rusyn I, Fujii H. Electron spin resonance and spin trapping technique provide direct evidence that edaravone prevents acute ischemia-reperfusion injury of the liver by limiting free radical-mediated tissue damage. Free Rad Res 2006;40:579-588.